Interferons and Monoclonal Antibodies in Immunomodulation

Interferons (IFNs)

Interferons are naturally occurring proteins (cytokines) that play a critical role in the body's innate immune response. In clinical practice, recombinant interferons—substances manufactured to be identical to those naturally found in the human body—are used to treat various infections and cancers.

Mechanisms of Action

Interferons possess three fundamental properties that drive their therapeutic use:

1. Antiviral: They protect human cells from viral attacks.
2. Antitumor: They prevent cancer cells from dividing and replicating.
3. Immunomodulating: They increase the activity of immune cells such as macrophages, neutrophils, and Natural Killer (NK) cells.

Interestingly, the immunomodulating effect is dual-natured. Interferons can augment the immune system to act as a defense against invaders, or they can inhibit the immune system to help manage autoimmune disorders where the body is attacking itself.

Types and Clinical Indications

Interferons are categorized into three main types: Alpha ($\alpha$), Beta ($\beta$), and Gamma ($\gamma$).

• IFN Alpha ($\alpha$): Often called "leukocyte IFNs" because they are produced from human leukocytes. They are used to treat viral infections like hepatitis and genital warts, as well as various cancers including chronic myelogenous leukemia, follicular lymphoma, hairy-cell leukemia, Kaposi’s sarcoma, and malignant melanoma.
• IFN Beta ($\beta$): Frequently used in the management of multiple sclerosis (MS).
• IFN Gamma ($\gamma$): Used for specific immunomodulatory needs.

Adverse Effects and Nursing Considerations

Patients receiving interferons often experience "flu-like" symptoms, including fever, chills, headache, and myalgia. However, the most significant dose-limiting adverse effect is fatigue. Other side effects may include anorexia, dizziness, nausea, vomiting, and diarrhea.

Exam Tip: Always check for allergies to the medication or albumin before administration, especially if the drug is being given intravenously.

Monoclonal Antibodies (MABs)

Monoclonal antibodies (MABs) represent a highly targeted approach to therapy. Unlike traditional chemotherapy, which can damage healthy cells, MABs are designed to specifically target cancer cells or specific immune proteins, resulting in fewer adverse effects. They are used extensively in treating cancer, rheumatoid arthritis (RA), multiple sclerosis (MS), and in organ transplantation.

Key Examples in Clinical Practice

Several MABs are essential to understand due to their specific targets and side effect profiles:

• Adalimumab (Humira): Targets Tumor Necrosis Factor (TNF). It is used for RA, Crohn’s disease, and ulcerative colitis. Common side effects include injection site inflammation and increased risk of upper respiratory or urinary tract infections.
• Belimumab (Benlysta): The first drug approved for Systemic Lupus Erythematosus (SLE); it works by inhibiting B-lymphocytes.
• Infliximab (Remicade): An anti-TNF agent used for Crohn’s and RA. Warning: Patients must be tested for Tuberculosis (TB) before starting this drug, as it carries a black box warning for fatal TB or fungal lung infections.
• Natalizumab: Used in the treatment of Multiple Sclerosis (MS) by inhibiting leukocyte adhesion mediated by alpha proteins. A rare but serious adverse effect is progressive multifocal leukoencephalopathy.

Summary of MAB Adverse Effects

While generally better tolerated than traditional antineoplastics, MABs can still cause:

• Flu-like symptoms (fever, chills, dyspnea).
• Specific risks such as infection, depression, or even malignancy depending on the specific agent.

In summary, the choice between an interferon or a monoclonal antibody depends on whether the goal is to stimulate a broad immune response against a virus or cancer, or to precisely target a specific protein to dampen an autoimmune attack.